Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression.
ATTRv amyloidosis
Amyloid cardiomyopathies
Amyloid neuropathies
Diagnostic techniques and procedures
Disease progression
Familial
Transthyretin
hATTR amyloidosis
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
03 10 2021
03 10 2021
Historique:
received:
19
03
2021
accepted:
18
07
2021
entrez:
4
10
2021
pubmed:
5
10
2021
medline:
7
10
2021
Statut:
epublish
Résumé
Hereditary transthyretin-mediated amyloidosis, also known as ATTRv amyloidosis (v for variant), is a rare, autosomal dominant, fatal disease, in which systemic amyloid progressively impairs multiple organs, leading to disability and death. The recent approval of disease-modifying therapies offers the hope of stabilization or eventual reversal of disease progression, and yet highlights a lack of disease-management guidance. A multidisciplinary panel of expert clinicians from France and the US came to consensus on monitoring the disease and identifying progression through a clinical opinion questionnaire, a roundtable meeting, and multiple rounds of feedback. A multidisciplinary team should monitor ATTRv amyloidosis disease course by assessing potential target organs at baseline and during follow-up for signs and symptoms of somatic and autonomic neuropathy, cardiac dysfunction and restrictive cardiomyopathy, and other manifestations. Variability in penetrance, symptoms, and course of ATTRv amyloidosis requires that all patients, regardless of variant status, undergo regular and standardized assessment in all these categories. Progression in ATTRv amyloidosis may be indicated by: worsening of several existing quantifiable symptoms or signs; the appearance of a new symptom; or the worsening of a single symptom that results in a meaningful functional impairment. We suggest that a multisystem approach to monitoring the signs and symptoms of ATTRv amyloidosis best captures the course of the disease. We hope this work will help form the basis of further, consensus-based guidance for the treatment of ATTRv amyloidosis.
Sections du résumé
BACKGROUND
Hereditary transthyretin-mediated amyloidosis, also known as ATTRv amyloidosis (v for variant), is a rare, autosomal dominant, fatal disease, in which systemic amyloid progressively impairs multiple organs, leading to disability and death. The recent approval of disease-modifying therapies offers the hope of stabilization or eventual reversal of disease progression, and yet highlights a lack of disease-management guidance. A multidisciplinary panel of expert clinicians from France and the US came to consensus on monitoring the disease and identifying progression through a clinical opinion questionnaire, a roundtable meeting, and multiple rounds of feedback.
MONITORING DISEASE AND PROGRESSION
A multidisciplinary team should monitor ATTRv amyloidosis disease course by assessing potential target organs at baseline and during follow-up for signs and symptoms of somatic and autonomic neuropathy, cardiac dysfunction and restrictive cardiomyopathy, and other manifestations. Variability in penetrance, symptoms, and course of ATTRv amyloidosis requires that all patients, regardless of variant status, undergo regular and standardized assessment in all these categories. Progression in ATTRv amyloidosis may be indicated by: worsening of several existing quantifiable symptoms or signs; the appearance of a new symptom; or the worsening of a single symptom that results in a meaningful functional impairment.
CONCLUSIONS
We suggest that a multisystem approach to monitoring the signs and symptoms of ATTRv amyloidosis best captures the course of the disease. We hope this work will help form the basis of further, consensus-based guidance for the treatment of ATTRv amyloidosis.
Identifiants
pubmed: 34602081
doi: 10.1186/s13023-021-01960-9
pii: 10.1186/s13023-021-01960-9
pmc: PMC8489116
doi:
Substances chimiques
Prealbumin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
411Informations de copyright
© 2021. The Author(s).
Références
Orphanet J Rare Dis. 2013 Feb 20;8:31
pubmed: 23425518
J Clin Pharm Ther. 2014 Jun;39(3):225-33
pubmed: 24749898
J Am Coll Cardiol. 2019 Jul 23;74(3):285-295
pubmed: 30885685
Amyloid. 2015;22(2):123-31
pubmed: 26017327
Ann Med. 2015;47(8):625-38
pubmed: 26611723
Clin Neurophysiol. 2018 Aug;129(8):1565-1569
pubmed: 29883834
Curr Opin Neurol. 2016 Feb;29 Suppl 1:S3-S13
pubmed: 26734951
Muscle Nerve. 2017 Nov;56(5):901-911
pubmed: 28063170
Clin Neurophysiol. 2016 May;127(5):2222-7
pubmed: 27072093
Amyloid. 2012 Jun;19 Suppl 1:61-4
pubmed: 22620968
Am J Ophthalmol. 2017 Nov;183:156-162
pubmed: 28911993
Heart Rhythm. 2012 Jul;9(7):1069-75
pubmed: 22387306
Amyloid. 2016;23(1):58-63
pubmed: 26852880
Eur Heart J. 2012 May;33(9):1120-7
pubmed: 21992998
J Am Geriatr Soc. 1991 Feb;39(2):142-8
pubmed: 1991946
Nat Rev Neurol. 2019 Jul;15(7):387-404
pubmed: 31209302
J Neurol. 2017 Nov;264(11):2293-2302
pubmed: 28983659
J Peripher Nerv Syst. 2005 Jun;10(2):158-73
pubmed: 15958127
J Am Coll Cardiol. 2016 Sep 6;68(10):1014-20
pubmed: 27585505
JAMA. 2013 Dec 25;310(24):2658-67
pubmed: 24368466
J Am Geriatr Soc. 2012 Apr;60(4):765-74
pubmed: 22329529
J Cardiovasc Magn Reson. 2016 Nov 30;18(1):89
pubmed: 27899132
Transplantation. 2015 Sep;99(9):1847-54
pubmed: 26308415
J Neurol Neurosurg Psychiatry. 2012 Feb;83(2):152-8
pubmed: 22228785
Circulation. 2012 Sep 4;126(10):1286-300
pubmed: 22949539
J Am Coll Cardiol. 2017 Jul 25;70(4):466-477
pubmed: 28728692
Amyloid. 2019 Sep;26(3):103-111
pubmed: 31339362
Proc Natl Acad Sci U S A. 2002 Dec 10;99 Suppl 4:16427-32
pubmed: 12351683
J Fr Ophtalmol. 2013 Nov;36(9):779-88
pubmed: 24144522
J Neurol. 2007 Dec;254(12):1684-8
pubmed: 18074076
Ther Adv Neurol Disord. 2013 Mar;6(2):129-39
pubmed: 23483184
Science. 1995 May 19;268(5213):1039-41
pubmed: 7754382
Amyloid. 2020 Sep;27(3):153-162
pubmed: 32131641
J Intern Med. 1994 May;235(5):479-85
pubmed: 8182405
JACC Heart Fail. 2019 Aug;7(8):709-716
pubmed: 31302046
Mt Sinai J Med. 2012 Nov-Dec;79(6):733-48
pubmed: 23239211
J Am Geriatr Soc. 2006 May;54(5):743-9
pubmed: 16696738
Eur Heart J. 2019 Apr 21;40(16):1287-1293
pubmed: 30753432
Hum Mutat. 2014 Sep;35(9):E2403-12
pubmed: 25044787
Rep Civ Aeromed Res Inst US. 1963 Apr;:1-8
pubmed: 14131272
J Neurol Sci. 2014 Sep 15;344(1-2):121-8
pubmed: 25012480
Rev Port Cardiol. 2017 May;36(5):333-340
pubmed: 28479268
Amyloid. 2018 Mar;25(1):8-10
pubmed: 29182024
ESC Heart Fail. 2020 Sep 13;:
pubmed: 32924285
J Peripher Nerv Syst. 2016 Mar;21(1):5-9
pubmed: 26663427
Curr Med Res Opin. 2013 Jan;29(1):63-76
pubmed: 23193944
Clin Genet. 1991 Sep;40(3):242-6
pubmed: 1685359
Circulation. 2017 Apr 4;135(14):1357-1377
pubmed: 28373528
Haematologica. 2019 Jul;104(7):1451-1459
pubmed: 30655373
J Cardiovasc Transl Res. 2015 Mar;8(2):117-27
pubmed: 25743445
Curr Heart Fail Rep. 2014 Mar;11(1):50-7
pubmed: 24464360
J Neuromuscul Dis. 2015 Jul 22;2(s2):S39-S48
pubmed: 27858761
Circulation. 2001 Dec 11;104(24):2911-6
pubmed: 11739305
J Clin Invest. 2018 Aug 1;128(8):3558-3567
pubmed: 30010620
N Engl J Med. 2018 Jul 05;379(1):22-31
pubmed: 29972757
J Am Coll Cardiol. 2018 Oct 23;72(17):2040-2050
pubmed: 30336828
J Med Genet. 2003 Nov;40(11):e120
pubmed: 14627687
Ann Neurol. 2015 Dec;78(6):901-16
pubmed: 26369527
J Neurol. 2020 Mar;267(3):703-712
pubmed: 31728713
JAMA Cardiol. 2016 Nov 1;1(8):880-889
pubmed: 27557400
Invest Ophthalmol Vis Sci. 1990 Mar 1;31(3):497-501
pubmed: 1690688
Mayo Clin Proc. 2012 Dec;87(12):1196-201
pubmed: 23218087
Amyloid. 2015;22(2):117-22
pubmed: 26096568
Eur Heart J. 2013 Feb;34(7):520-8
pubmed: 22745357
J Aging Phys Act. 2015 Apr;23(2):314-22
pubmed: 24812254
Mol Neurobiol. 2018 May;55(5):3676-3683
pubmed: 28527106
Amyloid. 2019 Mar;26(1):3-9
pubmed: 30793974
N Engl J Med. 2018 Jul 5;379(1):11-21
pubmed: 29972753
J Biol Chem. 1985 Sep 25;260(21):11793-8
pubmed: 4044580
Am Heart J. 2012 Aug;164(2):222-228.e1
pubmed: 22877808
JACC Cardiovasc Imaging. 2011 Jun;4(6):659-70
pubmed: 21679902
Neurology. 2007 Aug 14;69(7):693-8
pubmed: 17698792
JACC Cardiovasc Imaging. 2016 Dec;9(12):1432-1441
pubmed: 27838303
Heart. 2012 Nov;98(21):1546-54
pubmed: 22888163
Neurology. 2011 Jan 25;76(4):337-45
pubmed: 21263135
Circ Cardiovasc Imaging. 2013 Sep;6(5):627-36
pubmed: 23833285
Curr Opin Neurol. 2016 Feb;29 Suppl 1:S27-35
pubmed: 26734953
Clin Auton Res. 2019 Apr;29(2):245-251
pubmed: 29511897
Neurology. 2012 Aug 21;79(8):785-92
pubmed: 22843282
Cleve Clin J Med. 2009 Apr;76 Suppl 2:S37-40
pubmed: 19376980
Structure. 1997 May 15;5(5):595-600
pubmed: 9195890
Curr Opin Neurol. 2012 Oct;25(5):564-72
pubmed: 22941262
N Engl J Med. 2018 Sep 13;379(11):1007-1016
pubmed: 30145929
Biomed Res Int. 2015;2015:282405
pubmed: 26558262
Eur Heart J. 2018 Aug 7;39(30):2799-2806
pubmed: 29048471
Neurology. 2015 Aug 25;85(8):675-82
pubmed: 26208957